Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

QR Code

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Diabetic macular edema (DME) is the main cause of visual loss in patients with diabetic retinopathy. DME has been treated using intravitreal anti-vascular endothelial growth factor (VEGF) drugs, steroids, laser photocoagulation, vitreoretinal surgery, and their combinations. These modalities are gen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ren Aoki, Makoto Hatano, Fumiaki Higashijima, Takuya Yoshimoto, Masanori Mikuni, Tadahiko Ogata, Yuka Kobayashi, Makiko Wakuta, Kazuhiro Kimura
Format:	article
Language:	EN
Published:	Karger Publishers 2021
Subjects:	tissue plasminogen activator diabetic macular edema vitrectomized eye central retinal thickness visual acuity Ophthalmology RE1-994
Online Access:	https://doaj.org/article/a7bc3bcbc55f46a5a30e91fc8cfbb2e9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
by: Kumagai K, et al.
Published: (2019)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
by: Pessoa B, et al.
Published: (2021)

Pars Planectomy: Preliminary Report of a New Glaucoma Filtering Technique in Vitrectomized Eyes
by: Wangsupadilok B, et al.
Published: (2021)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021)

Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy
by: Chiara Altana, et al.
Published: (2021)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
by: Dweikat A, et al.
Published: (2021)

Multicenter, Prospective, Randomized Study of Dexamethasone Intravitreal Implant in Patients with Center-Involved Diabetic Macular Edema in the Asia-Pacific Region
by: Wei W, et al.
Published: (2021)

Effectiveness of 190 μg Fluocinolone Acetonide and 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
by: Zarranz-Ventura J, et al.
Published: (2020)

PLASMINOGEN ACTIVATOR OF YERSINIA PESTIS
by: V. V. Evseeva, et al.
Published: (2015)

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
by: Coelho J, et al.
Published: (2019)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
by: Campos Polo R, et al.
Published: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018)

Comment on ’Effectiveness of 190 μg Fluocinolone Acetonide versus 700 μg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis’ [Response to Letter]
by: Zarranz-Ventura J, et al.
Published: (2020)

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review
by: Belal M Firwana, et al.
Published: (2011)

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes
by: Udaondo P, et al.
Published: (2021)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
by: Van Aken E, et al.
Published: (2020)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016)

Inhibition of epithelial–mesenchymal transition in retinal pigment epithelial cells by a retinoic acid receptor-α agonist
by: Yuka Kobayashi, et al.
Published: (2021)

Effect of Tissue Plasminogen Activator on Treatment Outcome and Neuronal Degeneration in Acute Ischemic Stroke
by: Muhammad Masoud, et al.
Published: (2021)

Benzalkonium chloride-induced myofibroblastic transdifferentiation of Tenon’s capsule fibroblasts is inhibited by coculture with corneal epithelial cells or by interleukin-10
by: Chiemi Yamashiro, et al.
Published: (2021)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
by: Paulose R, et al.
Published: (2016)

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study
by: Joshi L, et al.
Published: (2016)

Edema hemorrágico agudo del lactante: reporte de un caso de presentación atípica
by: Yarmuch G,Paula, et al.
Published: (2012)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
by: Kiire CA, et al.
Published: (2015)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
by: Dugel PU, et al.
Published: (2016)

Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma
by: Yichao Wang, et al.
Published: (2021)

Edema fisiológico del recién nacido
by: ORTEGA,RAUL, et al.
Published: (1947)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
by: Ivanovska Adjievska B, et al.
Published: (2017)

Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample
by: Lehmann R, et al.
Published: (2021)

A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE)
by: Larsen J, et al.
Published: (2021)

EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE IN REFRACTORY DIABETIC MACULAR EDEMA
by: Ume Sughra, et al.
Published: (2021)

Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone
by: Zola M, et al.
Published: (2017)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
by: Chen YX, et al.
Published: (2020)

Experiencia de trombolisis sistematizada en infarto cerebral agudo en un hospital público de Chile
by: Figueroa-Reyes,Tatiana, et al.
Published: (2011)

Clinical therapeutic effects of intravitreal injection of Conbercept for macular edema in different types of retinal vein occlusion
by: Peng-Yao Lin, et al.
Published: (2021)

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
by: Iannetta D, et al.
Published: (2021)

Edema pulmonar de gran altura
by: UNDURRAGA M,FELIPE, et al.
Published: (2003)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
by: Kartasasmita A, et al.
Published: (2019)